蒙药乳腺-I号治疗乳腺增生症的机制研究进展
Research Progress on the Mechanism of Mongolian Medicine Ruxian-I in Treating Hyperplasia of Mammary Glands
摘要: 背景与目的：乳腺增生病(Hyperplasia of Mammary Glands, HMG)是女性的常见良性病变，其与乳腺癌的潜在关联备受关注。蒙药乳腺-I号在临床治疗HMG中显示出良好疗效，本文旨在系统综述其现代药理学作用机制。方法：对近年来关于蒙药乳腺-I号治疗乳腺增生的相关文献进行归纳与总结，从调节激素水平、影响细胞增殖与凋亡、改善代谢、抗氧化与抗炎等多维度阐述其多靶点作用机制。结果：蒙药乳腺-I号可通过下调血清雌二醇(E2)水平及乳腺组织ERα/PR表达，调控Bcl-2/Bax与CRYAB介导的细胞凋亡通路，抑制PCNA相关的细胞增殖，改善血脂代谢紊乱，并增强抗氧化酶活性及抑制炎症信号通路，从而发挥治疗作用。结论：这种通过调节“赫依、希拉、巴达干”三根平衡，进而疏通气血、分解异常黄水以治疗“七素布日勒都森”的策略，深刻体现了蒙医“整体观”的辨证论治思想，具有广阔的临床应用与研究前景。
Abstract: Background and Aims: Hyperplasia of mammary glands (HMG) is a common benign breast disease in women, and its potential association with breast cancer has attracted increasing attention. Mongolian medicine Ruxian-I has shown good therapeutic effects in the treatment of HMG. This article aims to systematically review the modern pharmacological mechanisms of Mongolian Medicine Ruxian-I. Methods: Relevant literature on the treatment of HMG with Mongolian medicine Ruxian-I in recent years was summarized and reviewed. Its multi-target mechanisms were elaborated from perspectives including regulating hormone levels, affecting cell proliferation and apoptosis, improving metabolism, and exerting antioxidant and anti-inflammatory effects. Results: Mongolian medicine Ruxian-I can treat HMG through various pathways, such as reducing serum estradiol (E2) levels and the expression of ERα/PR in mammary tissue, regulating the Bcl-2/Bax and CRYAB-mediated apoptosis pathways, inhibiting PCNA-related cell proliferation, improving dyslipidemia, enhancing antioxidant enzyme activities, and inhibiting inflammatory signaling pathways. Conclusion: Mongolian medicine Ruxian-I treats HMG through the synergistic effects of multiple components, targets, and pathways. Its characteristic of “holistic regulation” is highly consistent with Mongolian medical theory, showing broad prospects for clinical application and research.
文章引用：薛慧征, 王墨飞. 蒙药乳腺-I号治疗乳腺增生症的机制研究进展[J]. 临床个性化医学, 2026, 5(1): 392-397. https://doi.org/10.12677/jcpm.2026.51055

参考文献

[1] Burke, A., O’Driscoll, J., Abubakar, M., Bennett, K.E., Carmody, E., Flanagan, F., et al. (2025) A Systematic Review of Determinants of Breast Cancer Risk among Women with Benign Breast Disease. npj Breast Cancer, 11, Article No. 16. [Google Scholar] [CrossRef] 
[2] Kübler, K., Nardone, A., Anand, S., Gurevich, D., Gao, J., Droog, M., et al. (2025) Tamoxifen Induces PI3K Activation in Uterine Cancer. Nature Genetics, 57, 2192-2202. [Google Scholar] [CrossRef] 
[3] 刘兰涛. 蒙药乳腺-Ⅰ号干预下大鼠乳腺增生组织相关凋亡基因的表达[D]: [硕士学位论文]. 呼和浩特: 内蒙古民族大学, 2014.
[4] Zhang, J., Liu, J., Gong, G., Zhang, B. and Wei, C. (2019) Mongolian Medicine Ruxian-I Treatment of Estrogen-Induced Mammary Gland Hyperplasia in Rats Related to TCTP Regulating Apoptosis. Evi-dence-Based Complementary and Alternative Medicine, 1-10. [Google Scholar] [CrossRef] 
[5] Martier, A.T., Maurice, Y.V., Conrad, K.M., Carlino, D.A., Mauvais-Jarvis, F. and Mondrinos, M.J. (2025) Estradiol and Dihydrotestosterone Exert Sex-Specific Effects on Human Fibroblast and Endothelial Proliferation, Bioenergetics, and Vasculogenesis. Communications Biology, 8, Article No. 1422. [Google Scholar] [CrossRef] 
[6] 王忠超, 张彬, 任立群, 等. 蒙药乳腺-I号对乳腺增生大鼠雌激素及雌激素受体mRNA表达的影响[J]. 中国妇幼保健, 2014, 29(17): 2797-2799.
[7] 张彬. 蒙药乳腺-Ⅰ号治疗实验动物乳腺增生症的作用靶点及分子机制研究[Z]. 内蒙古民族大学. 2017-12-31.
[8] Estienne, A., Bongrani, A., Ramé, C., Ku-rowska, P., Błaszczyk, K., Rak, A., et al. (2021) Energy Sensors and Reproductive Hypothalamo-Pituitary Ovarian Axis (HPO) in Female Mammals: Role of mTOR (Mammalian Target of Rapamycin), AMPK (Amp-Activated Protein Kinase) and SIRT1 (Sirtuin 1). Molecular and Cellular Endocrinology, 521, Article 111113. [Google Scholar] [CrossRef] 
[9] 王忠超, 李跃华, 张彬, 等. 蒙药乳腺-I号对乳腺增生大鼠乳腺组织细胞增殖和凋亡的影响[J]. 中国生化药物杂志, 2014, 34(1): 56-58+61.
[10] Zhang, Y., Tian, L., Huang, G., Ge, X., Kong, F., Wang, P., et al. (2025) Structural Basis of BAX Pore Formation. Science, 388, eadv4314. [Google Scholar] [CrossRef] 
[11] Carver, J.A., Ecroyd, H., Truscott, R.J.W., Thorn, D.C. and Holt, C. (2018) Proteostasis and the Regulation of Intra- and Extracellular Protein Aggregation by ATP-Independent Molecular Chaperones: Lens α-Crystallins and Milk Caseins. Accounts of Chemical Research, 51, 745-752. [Google Scholar] [CrossRef] 
[12] 张俊飞. 基于细胞凋亡调控研究蒙药乳腺-Ⅰ号治疗乳腺增生的作用机制[D]: [硕士学位论文]. 呼和浩特: 内蒙古民族大学, 2018.
[13] Kang, S., Yoo, J. and Myung, K. (2024) PCNA Cycling Dynamics during DNA Replication and Repair in Mammals. Trends in Genetics, 40, 526-539. [Google Scholar] [CrossRef] 
[14] Hou, Y., Li, J., Zhang, Q. and Fan, Y. (2025) Association of Progesterone Recep-tor Status with Breast Cancer Prognosis: A Meta-Analysis. World Journal of Surgical Oncology, 23, Article No. 356. [Google Scholar] [CrossRef] 
[15] 杨雨民. 蒙药乳腺-Ⅰ号对乳腺增生大鼠ERK表达的影响研究[J]. 临床医药文献电子杂志, 2018, 5(96): 157.
[16] 王忠超, 李敏, 张彬, 等. 蒙药乳腺-Ⅰ号对乳腺增生大鼠抗氧化能力、乳腺组织雌激素受体和孕激素受体表达的影响[J]. 吉林大学学报(医学版), 2012, 38(6): 1052-1057+1036.